Updates on impurities in high blood pressure medicines
HSA would like to update the public on our actions and investigations into the potential contamination of angiotensin II receptor blockers (ARBs) with nitrosamine impurities such as N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). The ARB class of medicines is used for the control of high blood pressure. Please refer below for the latest updates.
|Types of communication||Date of release||Title|
|Pharmaceutical test method||15 May 2019||Testing methods for NDMA, NDEA and NMBA in Angiotensin II Receptor Blockers|
|Press Release||28 Mar 2019||HSA Recalls Three Brand of Losartan Medicines from Hetero Labs Ltd|
|HSA Update 3||07 Mar 2019||HSA Updates on Overseas Recall of Angiotensin II Receptor Blockers (NMBA impurity)|
|HSA Update 2||19 Dec 2018||HSA Updates on Overseas Recall of Angiotensin II Receptor Blockers (NDMA and NDEA impurities)|
|HSA Update 1||29 Aug 2018||HSA Updates on Overseas Recall of Valsartan Medicines (NDMA impurity)|